Latest News

e-Therapeutics announces that Steve Medlicott has been appointed Finance Director.

The full press release can be found here.

The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.  

It has a clinical pipeline of two drugs, ETS2101, which is in phase I trials for cancer, and ETS6103, which is in phase II development for depression


e-Therapeutics is listed on AIM with the ticker symbol ETX

David Cameron at eTherapeutics
British Prime Minister David Cameron and Prof. Malcolm Young, CEO of e-Therapeutics, shake hands as the Prime Minister opens our drug discovery centre at Oxford. more
Positive Results for ETS2101 trial

e-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours. The full press release can be found here.

ETS6103 trial

ETS6103 starts phase IIb trial, the full press release can be read here.

Update on ETS2101 phase I trial in brain cancer
No serious drug-related adverse events after five dose escalation steps; patients to be enrolled at higher dose levels.
The full press release can be read here.